Himadri Speciality Chemical Approves Final Dividend of Re. 0.80/Share, Re-appoints Independent Directors
Himadri Speciality Chemical's Board approved Q4 and FY26 results. A final dividend of Re. 0.80 per share (80%) is recommended. Independent Directors Mr. Girish Paman Vanvari and Mr. Gopal Ajay Malpani were re-appointed for a second 5-year term. The company will also incorporate a wholly-owned subsidiary in China.
The dividend recommendation and strategic expansion into China are significant positive developments for the company. The re-appointment of directors ensures continuity.
The company announced the approval of financial results, recommended a final dividend, and approved the re-appointment of independent directors and the incorporation of a foreign subsidiary, all of which are positive developments.
Himadri Speciality Chemical Limited announced the outcome of its Board of Directors meeting held on April 23, 2026. The Board approved the audited financial results (standalone and consolidated) for the quarter and financial year ended March 31, 2026.
The company recommended a final dividend of Re. 0.80 per equity share (80% of face value) for the financial year 2025-26, subject to shareholder approval. This dividend aggregates to ₹40.36 crore.
Further, the Board re-appointed M/s Ernst & Young, LLP as the Internal Auditor for the financial year 2026-27. Mr. Sambhu Banerjee was appointed as the Cost Auditor for the same period.
The Board also approved the re-appointment of Mr. Girish Paman Vanvari and Mr. Gopal Ajay Malpani as Independent Directors for a second term of five years, commencing June 22, 2026, and August 13, 2026, respectively, pending shareholder approval.
In a strategic move, the company approved the incorporation of a wholly-owned subsidiary in Guangzhou, China. The Board meeting commenced at 12:00 p.m. IST and concluded at 4:00 p.m. IST on April 23, 2026.
What to do with a filing like this
Himadri Speciality Chemical Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Himadri Speciality Chemical Limited. Read the original for the full detail.